MedTrace Logo

Aripiprazole, Abilify Maintena Collaborative Clinical Protocol

NCT02717130 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 9

Last updated 2020-04-13

Study results available
· View outcomes & findings →

Summary

An Open-label, Multi-center, Longitudinal, Within-subject Comparison Study to Evaluate the Effects of Aripiprazole Once Monthly in Subjects with Schizophrenia on 30-, 90-, and 180- day Re-hospitalization Rates Following Hospital Discharge Compared with Retrospective Re-hospitalization Rates while on Oral Antipsychotic Medication.

Conditions

Interventions

DRUG

Aripiprazole

Sponsors & Collaborators

  • Washington University School of Medicine

    collaborator OTHER

  • University of Missouri-Columbia

    collaborator OTHER

  • University of Missouri, Kansas City

    collaborator OTHER

  • Burrell Behavioral Health

    collaborator OTHER

  • Florida Atlantic University

    lead OTHER

Principal Investigators

  • John Newcomer, MD · Florida Atlantic University

  • Ginger Nicol, MD · Washington University School of Medicine

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-06-08
Primary Completion
2017-05-25
Completion
2017-05-25

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02717130 on ClinicalTrials.gov